Biogen’s Alzheimer’s hopeful aducanumab faces ‘less than a coin flip’s chance’ of FDA approval: analysts

When the FDA delayed its decision in Biogen’s controversial Alzheimer’s drug aducanumab in January, investors saw it as a positive. After all, it seemed the agency was at least willing to consider approving the drug in some form, despite the bruising thumbs-down it got from an advisory committee last November.